Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.86 USD | -0.06% | +8.08% | +13.23% |
04-18 | Alx Oncology Holdings Insider Sold Shares Worth $710,195, According to a Recent SEC Filing | MT |
04-10 | ALX Oncology Reports Positive Data From Ongoing Phase 1/2 Trial of Evorpacept | MT |
Business Summary
Number of employees: 72
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jaume Pons
FOU | Founder | 58 | 31/03/15 |
Jason Lettmann
CEO | Chief Executive Officer | 46 | 31/03/20 |
Peter García
DFI | Director of Finance/CFO | 62 | 31/12/19 |
Chief Tech/Sci/R&D Officer | - | 31/10/21 | |
Sophia Randolph
CTO | Chief Tech/Sci/R&D Officer | 56 | 31/05/16 |
Michael Chang
COO | Chief Operating Officer | - | 28/02/15 |
Shelly Pinto
AUD | Comptroller/Controller/Auditor | 48 | 02/05/21 |
Hong I. Wan
PRN | Corporate Officer/Principal | - | 31/03/15 |
Hank Stern
PRN | Corporate Officer/Principal | - | 31/12/14 |
Chris Byrd
LAW | General Counsel | - | 30/04/22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
J. Garland
BRD | Director/Board Member | 55 | 27/11/22 |
Corey Goodman
CHM | Chairman | 72 | 28/02/15 |
Jack Nielsen
BRD | Director/Board Member | 60 | 31/03/20 |
Jason Lettmann
CEO | Chief Executive Officer | 46 | 31/03/20 |
Rekha Hemrajani
BRD | Director/Board Member | 54 | 31/03/20 |
Jaume Pons
FOU | Founder | 58 | 31/03/15 |
Sophia Randolph
CTO | Chief Tech/Sci/R&D Officer | 56 | 31/05/16 |
Itziar Canamasas
BRD | Director/Board Member | 50 | 10/04/22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 50,498,816 | 39,460,945 ( 78.14 %) | 0 | 78.14 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.23% | 851M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+0.55% | 22.15B | |
-17.37% | 21.02B | |
-8.63% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ALXO Stock
- Company ALX Oncology Holdings Inc.